Apricus Biosciences (APRI) Receives Notice of Allowance from Korean Patent Office for Topical Cream to Treat Premature Ejaculation
Tweet
Share
E-mailGet Alerts APRI Hot Sheet
Join SI Premium – FREE
Apricus Biosciences, Inc. (Nasdaq: APRI) announced today that the Korean Patent Office recently issued a Notice of Allowance to grant a patent for the Company's development of a topical cream utilizing vasoactive prostaglandin E to treat premature ejaculation, When issued, the patent, entitled, "Compositions and Methods for the Treatment of Premature Ejaculation," will provide Korean patent protection until March 2024.
It is one in a series of issued patents and pending applications that Apricus Bio owns in the male sexual dysfunction field utilizing its proprietary NexACT technology, which includes its Vitaros product to treat erectile dysfunction, among others in research and development.
It is one in a series of issued patents and pending applications that Apricus Bio owns in the male sexual dysfunction field utilizing its proprietary NexACT technology, which includes its Vitaros product to treat erectile dysfunction, among others in research and development.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Sky Quarry names Heidi Bowman as CFO
- Albemarle names Max Hood as chief accounting officer
- Sky Century Investment responds to OTC Markets stock promotion inquiry
Create E-mail Alert Related Categories
Corporate News, FDASign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
